Ranked #1 in 8 out of the 10 evaluated specialties by U.S. News
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
As a member of the Boston Comprehensive Sickle Cell Center and the New England Pediatric Sickle Cell Consortium, the Sickle Cell Disease Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center provides diagnosis, treatment and long-term health management for children and young adults with all types of sickle cell disease. We treat sickle cell trait (HbAS), sickle cell anemia (HbSS), sickle cell with hemoglobin C disease (HbSC), and hemoglobin S-beta-thalassemia, as well as less common forms of the disease (HbSE, HbSO and HbSD).
Dana-Farber/Boston Children’s is an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children’s Hospital. We offer, in one specialized program, the full spectrum of services that are needed for diagnosis, treatment and ongoing care of even the rarest and hard-to-treat conditions.
The Sickle Cell Program treatment teams are staffed by experienced pediatric hematologists, nurse practitioners and physician assistants with extensive experience treating and managing sickle cell disease. Children treated in our program also receive care from other specialty physicians since sickle cell disease can affect nearly every major organ in the body. All of our patients are assigned a social worker, who helps them manage the challenges of ongoing treatment, providing emotional, psychological and logistical support.
We are one of 10 sickle cell centers in the United States funded by the National Institutes of Health, and we are a site for the Sickle Cell Disease Clinical Research Network. In our laboratories and clinic, physicians and scientists conduct studies to increase knowledge about sickle cell disorders and to enhance the treatment of children affected by these conditions. Currently, they are developing new methods to diagnose and treat sickle cell disease, including stem cell transplantation and gene therapy.
Learn more about our Sickle Cell Disease Program on the Dana-Farber/Boston Children’s website.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”